[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201690613A1 - Улучшенные составы на основе аденовирусов - Google Patents

Улучшенные составы на основе аденовирусов

Info

Publication number
EA201690613A1
EA201690613A1 EA201690613A EA201690613A EA201690613A1 EA 201690613 A1 EA201690613 A1 EA 201690613A1 EA 201690613 A EA201690613 A EA 201690613A EA 201690613 A EA201690613 A EA 201690613A EA 201690613 A1 EA201690613 A1 EA 201690613A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adenoviruses
compositions based
improved compositions
pharmaceutical compositions
improved
Prior art date
Application number
EA201690613A
Other languages
English (en)
Other versions
EA036046B1 (ru
Inventor
Яник Адриансен
Original Assignee
Круселл Холланд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Круселл Холланд Б.В. filed Critical Круселл Холланд Б.В.
Publication of EA201690613A1 publication Critical patent/EA201690613A1/ru
Publication of EA036046B1 publication Critical patent/EA036046B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В настоящем изобретении представлены фармацевтические составы на основе аденовирусов, в частности жидкие фармацевтические составы, содержащие аденовирусы.
EA201690613A 2013-09-19 2014-09-16 Композиция для стабилизации количества, эффективности, инфекционности и качества аденовирусов EA036046B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13185200 2013-09-19
PCT/EP2014/069654 WO2015040002A1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations

Publications (2)

Publication Number Publication Date
EA201690613A1 true EA201690613A1 (ru) 2016-08-31
EA036046B1 EA036046B1 (ru) 2020-09-18

Family

ID=49212683

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690613A EA036046B1 (ru) 2013-09-19 2014-09-16 Композиция для стабилизации количества, эффективности, инфекционности и качества аденовирусов

Country Status (32)

Country Link
US (3) US9974737B2 (ru)
EP (1) EP3046536B1 (ru)
JP (1) JP6013654B2 (ru)
KR (1) KR102258348B1 (ru)
CN (2) CN111514314A (ru)
AP (1) AP2016009154A0 (ru)
AU (1) AU2014323230B2 (ru)
BR (1) BR112016005761B1 (ru)
CA (1) CA2923352C (ru)
CL (1) CL2016000621A1 (ru)
CY (1) CY1122796T1 (ru)
DK (1) DK3046536T3 (ru)
EA (1) EA036046B1 (ru)
ES (1) ES2711115T3 (ru)
HR (1) HRP20182159T1 (ru)
HU (1) HUE041791T2 (ru)
IL (1) IL244572A (ru)
LT (1) LT3046536T (ru)
ME (1) ME03324B (ru)
MX (1) MX369156B (ru)
MY (1) MY181190A (ru)
NZ (1) NZ717156A (ru)
PE (1) PE20160527A1 (ru)
PH (1) PH12016500316B1 (ru)
PL (1) PL3046536T3 (ru)
PT (1) PT3046536T (ru)
RS (1) RS58393B1 (ru)
SG (1) SG11201601181SA (ru)
SI (1) SI3046536T1 (ru)
TR (1) TR201900274T4 (ru)
WO (1) WO2015040002A1 (ru)
ZA (1) ZA201601919B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2715378T3 (es) 2013-04-25 2019-06-04 Janssen Vaccines & Prevention Bv Polipéptidos F de prefusión del virus sincicial respiratorio (RSV) solubles y estabilizados
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
SI3046536T1 (sl) 2013-09-19 2019-05-31 Janssen Vaccines & Prevention B.V. Izboljšane formulacije adenovirusa
EA035909B1 (ru) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv до слияния
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR20180061264A (ko) * 2015-10-06 2018-06-07 얀센 백신스 앤드 프리벤션 비.브이. 플라스틱으로 인한 생물학적 약제 분해를 방지하는 방법
BR112018011711A2 (pt) 2015-12-11 2018-12-04 California Inst Of Techn peptídeos de direcionamento para direcionar virus adeno-associados (aav)
EP3439694A1 (en) 2016-04-05 2019-02-13 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CN116063551A (zh) 2016-04-05 2023-05-05 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f蛋白
JP2019523644A (ja) 2016-05-30 2019-08-29 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された融合前ｒｓｖ ｆタンパク質
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
CN113438943A (zh) * 2019-01-09 2021-09-24 辛克库姆公司 稳定的无包膜病毒组合物
CN117999353A (zh) * 2021-07-08 2024-05-07 拜奥卡德联合股份公司 无包膜病毒的药物组合物
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
WO2024079657A1 (en) * 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Formulations for aav gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2350890C (en) * 1998-11-16 2014-07-08 Introgen Therapeutics, Inc. Aqueous compositions for long-term stable storage of adenovirus particles including uses and methods for preparing same
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1453537A1 (en) * 2001-12-12 2004-09-08 FH Faulding & Co. Limited Composition for viral preservation
AU2002366809A1 (en) * 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CN101396555A (zh) * 2003-06-04 2009-04-01 坎基股份有限公司 用于干扰素治疗的方法和组合物
WO2005012407A2 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
EP1692279A4 (en) * 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
US8137966B2 (en) * 2004-03-04 2012-03-20 Dainippon Sumitomo Pharma Co., Ltd. Rat embryonic stem cell
SG159554A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
GB0715723D0 (en) * 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
EP2473191B1 (en) * 2009-09-04 2017-08-23 XOMA Technology Ltd. Antibody coformulations
GB201002419D0 (en) 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
EA201391043A1 (ru) 2011-02-17 2014-03-31 Сентисс Фарма Прайвет Лимитед Способ и композиция для замедления сорбции консервантов пластиками
SI3046536T1 (sl) * 2013-09-19 2019-05-31 Janssen Vaccines & Prevention B.V. Izboljšane formulacije adenovirusa
CN104027815A (zh) 2014-06-12 2014-09-10 中国农业科学院兰州畜牧与兽药研究所 一种丹参酮包合液及其制备方法和应用
KR20180061264A (ko) 2015-10-06 2018-06-07 얀센 백신스 앤드 프리벤션 비.브이. 플라스틱으로 인한 생물학적 약제 분해를 방지하는 방법

Also Published As

Publication number Publication date
US20180235871A1 (en) 2018-08-23
JP6013654B2 (ja) 2016-10-25
IL244572A (en) 2017-02-28
US11484494B2 (en) 2022-11-01
CN111514314A (zh) 2020-08-11
JP2016530220A (ja) 2016-09-29
ES2711115T3 (es) 2019-04-30
MX369156B (es) 2019-10-30
ME03324B (me) 2019-10-20
EP3046536B1 (en) 2018-11-28
US20190240146A1 (en) 2019-08-08
LT3046536T (lt) 2019-03-12
KR20160055180A (ko) 2016-05-17
US9974737B2 (en) 2018-05-22
HRP20182159T1 (hr) 2019-02-22
DK3046536T3 (en) 2019-03-11
PH12016500316A1 (en) 2016-05-02
BR112016005761B1 (pt) 2022-09-20
CL2016000621A1 (es) 2016-11-25
PT3046536T (pt) 2019-02-25
HUE041791T2 (hu) 2019-05-28
CN105530917A (zh) 2016-04-27
RS58393B1 (sr) 2019-04-30
WO2015040002A1 (en) 2015-03-26
IL244572A0 (en) 2016-04-21
CY1122796T1 (el) 2021-05-05
AU2014323230A1 (en) 2016-03-17
CA2923352A1 (en) 2015-03-26
ZA201601919B (en) 2017-06-28
SI3046536T1 (sl) 2019-05-31
AU2014323230B2 (en) 2017-05-25
PE20160527A1 (es) 2016-05-20
KR102258348B1 (ko) 2021-05-31
MX2016003414A (es) 2016-06-30
AP2016009154A0 (en) 2016-04-30
CA2923352C (en) 2022-05-03
US20160199426A1 (en) 2016-07-14
TR201900274T4 (tr) 2019-02-21
MY181190A (en) 2020-12-21
SG11201601181SA (en) 2016-04-28
NZ717156A (en) 2022-04-29
PH12016500316B1 (en) 2016-05-02
US10272032B2 (en) 2019-04-30
EA036046B1 (ru) 2020-09-18
EP3046536A1 (en) 2016-07-27
CN105530917B (zh) 2020-06-05
PL3046536T3 (pl) 2019-06-28
BR112016005761A2 (ru) 2017-08-01

Similar Documents

Publication Publication Date Title
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201790380A1 (ru) Ингибиторы mk2 и их применения
CL2016000257A1 (es) Composiciones edulcorantes.
CL2016000258A1 (es) Composiciones edulcorantes.
UY4234Q (es) Configuración aplicada en zapato
DK2986726T3 (da) Hidtil ukendte bacillusstammesammensætninger
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
UY4210Q (es) Silla
UY4223Q (es) Banco
FR3007636B1 (fr) Trocart perforant.
EA202092926A3 (ru) Лиофилизированные составы, содержащие фактор ix
ES2651188T8 (es) Composición líquida fotopolimerizable
UY34677A (es) Imidazopiridazinas sustituidas
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BR112014032501A2 (pt) composto, e, composição farmacêutica.
UY4314Q (es) Configuracion aplicada en zapato
UY4243Q (es) Banco
CL2016000836A1 (es) Composiciones de péptidos nuevas.
BR112016010562A2 (pt) composição antitranspirante.
UY4233Q (es) Configuración aplicada en zapato
FR3015283B1 (fr) Composition comprenant une forte teneur d'hydrolat
EA201792492A1 (ru) Aml-антигены и их применение
TN2014000522A1 (fr) لوح مدرسي بوجهين
UY4267Q (es) Botella

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ KG TJ TM